Cyril Amarchand Mangaldas (CAM), Sullivan & Cromwell LLP (S&C), White & Case, AZB & Partners along with advised on the acquisition of Organon by Sun Pharmaceuticals.
Cyril Amarchand Mangaldas (CAM) advised Organon & Co. (NYSE: OGN), a global healthcare company, with diverse portfolio across women’s health, biosimilars, and therapies and products for a wide range of conditions and diseases, in its acquisition by Sun Pharmaceutical Holdings USA, Inc., a U.S. subsidiary of Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA), the leading pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
The transaction team was led by Partner Ruetveij Pandya, and Partner Saloni Shroff, with assistance from Principal Associate Abhilasha Malpani and Associates Sajith Anjickal, Chelsea Sawlani, Neelanshi Gupta, Simran Srivastava, and Shravan Subramanian.
Rishabh Shroff, Partner (Co-Head – Private Client and Head – International Business Development); provided strategic inputs and guidance.
Partner Meeta Kurpad, with support from Manasvin Andra, advised on financing aspects of the transaction.
Sullivan & Cromwell LLP is serving as legal advisor to Organon.
White & Case LLP is serving as legal advisor and AZB & Partners is serving as legal advisor for India related matters to Sun Pharma.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
